Warwick Week – JLR, Inbetweeners, Digital Healthcare, Warwick Ventures and Alzheimer's
Warwick in the News
Jaguar Land Rover advanced research group to relocate to the University of Warwick
Jaguar Land Rover is to relocate its 170-person advanced research group to the University of Warwick as part of a strategy to raise vehicle production from fewer than 100,000 to 300,000 a year.
Read more on FT.com >>
The Inbetweeners take “A Trip to Warwick”
The latest episode of hit comedy The Inbetweeners saw the guys take a trip to “Warwick”. The show aired on Monday 4th October but as our alumni will have noticed, the show wasn’t actually filmed at Warwick at all!
Find out more on E4.com >>
New Institute of Digital Healthcare
The University of Warwick has joined forces with NHS West Midlands to create the new Institute of Digital Healthcare, a collaboration aimed at improving people’s health and wellbeing through the use of innovative technologies. The Institute was officially launched on Wednesday 6th October.
Read the Press Release >>
Launch of Warwick Ventures Ltd!
After 10 years helping Warwick academics launch spin-out companies and commercialise their research, the University of Warwick's technology transfer office is set to become a spin-out company in its own right. Warwick Ventures Ltd will be launched to a selection of invited guests at London's Buckingham Gate hotel on Monday October 11at an event that will also celebrate the organisation's achievements over the past decade.
Visit the Warwick Ventures website >>
Professor of Clinical Pharmacology at University of Warwick backs Alzheimer's drug U-turn by NICE
Professor Donald Singer, Professor of Clinical Pharmacology and Therapeutics at the University of Warwick has spoken in support of new plans to allow access to drugs for patients in the early stages of Alzheimer's disease.
Current rules prevent doctors prescribing three drugs, donepezil, galantamine and rivastigmine, in early cases of the disease. However, the National Institute for Health and Clinical Excellence (NICE) now says evidence backs the use of drugs for mild symptoms.
Professor Donald Singer said:
The proposal by NICE to extend its guidance to include access for 3 drugs (donepezil, galantamine and rivastigimine) to patients with much milder disease than previously eligible is excellent news for patients with Alzheimer's disease and their families. It is also very encouraging to have in the guidance a new treatment option (memantine) for patients with more severe disease.
People with serious conditions such as Alzheimer's may naturally express concern about how long this has taken. However it is essential that health policy makers have convincing evidence both for effectiveness and risk before making a medicine available to people who could benefit. Consider the recent public concern about regulation of the diabetes drug rosiglitazone, for which an unexpected increase in cardiovascular risk appears to have occurred after it became widely available. It will still be very important to remain vigilant for possible unexpected risks of the Alzheimer's treatments, as these drugs will now be exposed to large numbers of people, who may also be medically more complex, and therefore more at risk of adverse effects, than in the clinical trials on which the NICE guidance has been based.
Read the article on the Telegraph website >>
Add a commentYou are not allowed to comment on this entry as it has restricted commenting permissions.